Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-MTAB-9712

ABSTRACT: RNA-seq of Huh7 cell after G6PD enzyme activity inhibitor RRx-1 treated with 20μM concentrations for 24h

PROVIDER: E-MTAB-9712 | ExpressionAtlas | 2020-12-09

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-MTAB-9712-analysis-methods.tsv	Tabular
	E-MTAB-9712-analytics.tsv	Tabular
	E-MTAB-9712-atlasExperimentSummary.Rdata	Rdata
	E-MTAB-9712-configuration.xml	Xml
	E-MTAB-9712-g2_g1-mvaPlot.png	Other

Items per page:

1 - 5 of 20

Similar Datasets

RNA-seq of Huh7 cell after G6PD enzyme activity inhibitor RRx-1 treated with 20μM concentrations for 24h

Project description:RNA-seq of Huh7 cell after G6PD enzyme activity inhibitor RRx-1 treated with 20μM concentrations for 24h

| PRJEB41054 | ENA

RNA-seq of Huh7 cell after G6PD enzyme activity inhibitor RRx-1 treated with 20μM concentrations for 24h

Project description:In order to analyze the changes of G6PD enzyme activity regulating the metabolism and proliferation pathways in HCC cell. After G6PD enzyme activity inhibitor RRx-1 treated with 20μM concentrations for 24h in Huh7 cell. Differential expression of genes were selected after RNA sequencing. Then David Bioinformatics was utilized to identify the most significantly regulated GOTERMs and KEGG pathways based on the transcriptional changes.

2020-11-12 | E-MTAB-9712 | biostudies-arrayexpress

Multi range ERK responses shape the proliferative trajectory of single cells following oncogenic induction

Project description:Aberrant oncogene activation can promote cellular transformation and tumorigenesis, enabling cancer cells to grow and proliferate uncontrollably. For instance, activating Ras or Raf mutations bypass the need of growth factor stimulation, resulting in constitutive mitogenic signaling through the Ras or Raf to MAPK pathway. Surprisingly, in normal cells, the same oncogenic mutations typically cause cells to enter into a stable state of cell cycle arrest, a phenomenon known as oncogene-induced senescence. We hypothesized that players that mediate ERK activity-dependent cell fate decisions must themselves undergo some expression/activity changes in response to varying levels of ERK activity. To systematically identify gene expression changes associated with different levels of ERK activity, we performed deep RNA sequencing of RPE cells simultaneously treated, for varying lengths of time, with DOX (to induce BRAFV600E) and different concentrations of ERK inhibitors. The ERK inhibitor concentrations were chosen to include most dynamic ranges of proliferation response based on previous titration experiments. The time points include 0 (untreated control), 1, 2, 4, 8, 16 and 24h post DOX and drug treatment. These time points were selected based on the observation that RPE cells already showed a bell-shaped correlation between ERK activity and proliferation as early as 24h after BRaf induction. Moreover, earlier time points allow enrichment of genes that are more directly responsive to ERK activity changes.

2021-07-16 | GSE180210 | GEO

Effects of fosfomycin on biofilm of a clinical Staphylococcus aureus isolated from osteoarticular infection by transcriptomal approach

Project description:The aim of the present study was to investigate the mechanisms by which fosfomycin restrains biofilm formation and affects a 24h-old biofilm of S. aureus. RNA sequencing (RNA-Seq) technology was used to compare the transcriptomes of S. aureus biofilms formed or treated with sublethal concentrations of fosfomycin.

2018-01-31 | GSE83269 | GEO

ChIP-Seq for transcriptional regulators and RNA Polymerase II in tumor cells treated with JQ1

Project description:ChIP-Seq of RNA Polymerase II, and transcriptional regulators in multiple myeloma (MM.1S), glioblastoma (U87-MG), and small cell lung carcinoma (H2171) treated with the BET bromodomain inhibitor JQ1. Cell lines (MM.1S, U87-MG, and H2171) representing multiple myeloma, glioblastoma, and small cell lung carcinoma, were treated with varying concentrations (5nM to 5µM) of the BET bromodomain inhibitor JQ1 followed by ChIP-Seq for RNA Polymerase II and transcriptional regulators. Other datasets from this series of experiments have been release as a part of GSE42355.

2013-07-26 | E-GEOD-49224 | biostudies-arrayexpress

Effect of cabozantinib on transcriptome and signaling pathways in leukemic cell line Kasumi-1

Project description:To identify molecular effects of the tyrosine kinase inhibitor cabozantinib (XL184), we applied gene expression profiling on human acute leukemic cell lines Kasumi-1, which harbors t(8;21) coupled with KIT mutation, by Whole Transcriptome Shotgun Sequencing (RNA-seq). After Kasumi-1 cells were treated with 100nM cabozantinib for 4h or 24h, differentially expressed genes (DEGs) of 124 genes upregulated and 416 were downregulated in 4h, and 184 genes upregulated and 69 genes were downregulated in 24h treatment, compared with vehicle group.

2021-04-22 | GSE153853 | GEO

RNA-seq of DNMT1 inhibitor treated AML cell lines

Project description:RNA-seq of DNMT1 inhibitor treated AML cell lines

| PRJNA558691 | ENA

Proteomics analysis of differentially expressed proteins in response to Mdm2 knockdown or treatment with Mdm2 inhibitor, MEL23

Project description:Tumor cells had Mdm2 silenced through transfection with siRNAs (two siRNAs against Mdm2 or siCtrl) or its activity inhibited through treatment with Mdm2 inhibitor, MEL23, for 24h. Total cell lysate was processed for untargeted proteomics analysis.

2023-05-10 | PXD033789 | JPOST Repository

Proteome alterations in MLL-rearranged leukemia cells following WIN Site inhibition

Project description:WIN Site inhibitors bind the WIN Site of WDR5 resulting in decreased transcription of WDR5 target genes, many of which encode components of the protein synthesis machinery. In this study, we determined proteome alterations in an MLL-rearranged leukemia cell line treated for either 24 or 72 hours with a WIN Site inhibitor. The data from these studies, along with Ribo-Seq, RNA-Seq, and CRISPR screen experiments, guided us in assembling a collection of compounds that, when combined with WIN Site inhibitor, synergistically inhibit growth of MLL-rearranged leukemia cells.

2023-07-04 | PXD035129 | Pride

RNA-seq HepG2 cell line treated with TRPV2 inhinitor or agonist

Project description:HepG2 cell line was co-cultured with 1ml/L Fat emulsion, after 24h treatment with agonist (2-APB) or inhibitor (SKF-96365). RNA-seq was performed.

2023-12-01 | GSE221726 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data